| Stereochemistry | RACEMIC |
| Molecular Formula | C31H32N4O3 |
| Molecular Weight | 508.6108 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C1=C(C)C=C(CN2C=NC3=C2CC(N(C3)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5)C(O)=O)C=C1
InChI
InChIKey=YSTVFDAKLDMYCR-UHFFFAOYSA-N
InChI=1S/C31H32N4O3/c1-21-16-22(14-15-26(21)33(2)3)18-34-20-32-25-19-35(28(31(37)38)17-27(25)34)30(36)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-16,20,28-29H,17-19H2,1-3H3,(H,37,38)
| Molecular Formula | C31H32N4O3 |
| Molecular Weight | 508.6108 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
CNS Activity
Originator
Approval Year
PubMed
Sample Use Guides
Sixteen normal subjects received an intravenous infusion of PD123319 (10 mcg/minute for 5 minutes) and placebo, separated by one week.
Route of Administration:
Intravenous
The addition of 10(-6)M PD122319 to human arteries twenty minutes before
the stimulation of vasoconstriction by angiotensin
II caused a small but significant inhibition of
vasoconstriction by 20%. In other
arteries, the addition of 10(-6)M PD122319 twenty
minutes before the stimulation of vasoconstriction
by angiotensin II significantly enhanced
vasoconstriction, maximally by 60%.
